Grant of Share Options

RNS Number : 0256M

Provexis PLC

11 September 2019

 

11 September 2019

Provexis plc

("Provexis" or the "Company")

Grant of Share Options

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that it has today awarded a total of 62,500,000 options ('Options') over ordinary shares of 0.1 pence each in the Company ('Ordinary Shares') under the Provexis 2005 share option scheme to certain directors and scientific, sales and marketing consultants to the Company.

These Options will have an exercise price of 0.30 pence, being the closing mid-market price on 10 September 2019, and they are subject to performance criteria (including Ordinary Share price appreciation). The Options are exercisable, subject to vesting, between 1 April 2022 and 10 years from the date of grant.

A total of 58,000,000 Options have been awarded to the following directors:

Director	No. of options granted	Existing no. of options	Total no. of options over Ordinary Shares ('Total Options')	Total Options as a percentage of the Company's issued share capital
Dawson Buck - Chairman	8,000,000	17,000,000	25,000,000	1.26
Ian Ford - CEO & CFO	25,000,000	25,000,000	50,000,000	2.52
Niamh O'Kennedy - CSO	25,000,000	13,000,000	38,000,000	1.92

Following the issue of the new Options, the total number of Ordinary Shares under option which could be issued if all of the performance criteria are met is 193,500,000 Ordinary Shares, representing 9.8 per cent. of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dawson Buck - Chairman Ian Ford - CEO & CFO Niamh O'Kennedy - CSO
2	Reason for the notification
a)	Position/status	See 1 a) above
b)	Initial notification / Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PROVEXIS PLC
b)	LEI	21380042E3Y3N9VZ6N48
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.1p each ISIN: GB00B0923P27
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Director/PDMR  Price(s) Volume(s) Dawson Buck - Chairman 0.30p per share 8,000,000 Ian Ford - CEO & CFO 0.30p per share 25,000,000 Niamh O'Kennedy - CSO 0.30p per share 25,000,000
d)	Aggregated information - Aggregated volume - Price	Price(s) Volume(s) 0.30p per share 58,000,000
e)	Date of the transaction	11 September 2019
f)	Place of the transaction	Outside a trading venue

For further information please contact:

Provexis plc Dawson Buck, Chairman Ian Ford, CEO & CFO	Tel:         [phone]                 [e-mail]
Allenby Capital Limited Nick Naylor / Liz Kirchner	Tel:         [phone]

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com and www.fruitflowplus.com.

 

END

 

 

DSHEFLFFKKFBBBB